Author:
Basnet Saru,Santos Joao M.,Quixabeira Dafne C.A.,Clubb James H.A.,Grönberg-Vähä-Koskela Susanna A.M.,Arias Victor,Pakola Santeri,Kudling Tatiana V.,Heiniö Camilla,Havunen Riikka,Cervera-Carrascon Victor,Sorsa Suvi,Anttila Marjukka,Kanerva Anna,Hemminki Akseli
Subject
Pharmacology (medical),Cancer Research,Oncology,Molecular Medicine
Reference61 articles.
1. Oncolytic adenovirus and gene therapy BiTE for the treatment of with EphA2- grade gliomas;Arnone;J. Immun. Can.,2021
2. NC-ND license BiTE secretion from in situ-programmed myeloid cells results in tumor-retained pharmacology;Hao;J. Control Release,2022
3. The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types;Einsele;Cancer,2020
4. Are BiTEs the “missing link” in cancer therapy?;Suryadevara;Oncoimmunology,2015
5. Oncolytic herpesvirus expressing PD- BiTE for cancer therapy : exploiting tumor immune suppression as an opportunity for targeted immunotherapy;Khalique;J. Immun. Can.,2021
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献